Efficacy of the Rho-Kinase Inhibitor for Corneal Endothelial Protection in Fuchs Endothelial Corneal Dystrophy After Phacoemulsification.

IF 1.9 3区医学 Q2 OPHTHALMOLOGY

Cornea Pub Date : 2025-02-12 DOI:10.1097/ICO.0000000000003827

Benjama Keeratidamkerngsakul, Vilavun Puangsricharern, Susama Chokesuwattanaskul, Krit Pongpirul, Thanachaporn Kittipibul

{"title":"Efficacy of the Rho-Kinase Inhibitor for Corneal Endothelial Protection in Fuchs Endothelial Corneal Dystrophy After Phacoemulsification.","authors":"Benjama Keeratidamkerngsakul, Vilavun Puangsricharern, Susama Chokesuwattanaskul, Krit Pongpirul, Thanachaporn Kittipibul","doi":"10.1097/ICO.0000000000003827","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the efficacy of Rho-kinase (ROCK) inhibitors in corneal endothelial protection in Fuchs endothelial corneal dystrophy (FECD) after phacoemulsification.Methods: Forty-eight eyes from 31 patients with FECD and cataracts were randomly assigned to receive either the topical ROCK inhibitor (or ripasudil) or placebo 4 times a day, in addition to the standard antibiotic and antiinflammatory eye drops, for 1 month after phacoemulsification. Endothelial cell density (ECD), central corneal thickness (CCT), and corneal densitometry were measured. The primary outcome was the central ECD (C-ECD) loss percentage 3 months after phacoemulsification. Secondary outcomes included C-ECD loss and paracentral ECD loss percentages and the CCT change ratio at different time points after phacoemulsification. Adverse events were evaluated.Results: There was significantly less cell loss among those eyes treated with ripasudil. C-ECD significantly increased from a baseline of 2361 cells/mm2 (95% confidence interval, 2151-2571) to 2506 cells/mm2 (95% confidence interval, 2296-2716) 3 months after phacoemulsification. The paracentral ECD loss was 0.4% in the ripasudil group versus 7.3% in the control group. Corneal densitometry remained relatively unchanged in the ripasudil group but increased significantly over time in the control group. The mean CCT increased slightly in both groups from baseline to the final follow-up at 3 months, albeit without significant differences between the groups. In the ripasudil group, transient conjunctival erythema was the most common adverse event.Conclusions: The topical ROCK inhibitor, or ripasudil, demonstrated beneficial effects on preventing endothelial cell loss and improving endothelial function in patients with FECD undergoing phacoemulsification. Corneal densitometry showed reduced corneal light scattering in the ripasudil group after phacoemulsification, suggesting improved corneal endothelial function.","PeriodicalId":10710,"journal":{"name":"Cornea","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cornea","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ICO.0000000000003827","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the efficacy of Rho-kinase (ROCK) inhibitors in corneal endothelial protection in Fuchs endothelial corneal dystrophy (FECD) after phacoemulsification.

Methods: Forty-eight eyes from 31 patients with FECD and cataracts were randomly assigned to receive either the topical ROCK inhibitor (or ripasudil) or placebo 4 times a day, in addition to the standard antibiotic and antiinflammatory eye drops, for 1 month after phacoemulsification. Endothelial cell density (ECD), central corneal thickness (CCT), and corneal densitometry were measured. The primary outcome was the central ECD (C-ECD) loss percentage 3 months after phacoemulsification. Secondary outcomes included C-ECD loss and paracentral ECD loss percentages and the CCT change ratio at different time points after phacoemulsification. Adverse events were evaluated.

Results: There was significantly less cell loss among those eyes treated with ripasudil. C-ECD significantly increased from a baseline of 2361 cells/mm2 (95% confidence interval, 2151-2571) to 2506 cells/mm2 (95% confidence interval, 2296-2716) 3 months after phacoemulsification. The paracentral ECD loss was 0.4% in the ripasudil group versus 7.3% in the control group. Corneal densitometry remained relatively unchanged in the ripasudil group but increased significantly over time in the control group. The mean CCT increased slightly in both groups from baseline to the final follow-up at 3 months, albeit without significant differences between the groups. In the ripasudil group, transient conjunctival erythema was the most common adverse event.

Conclusions: The topical ROCK inhibitor, or ripasudil, demonstrated beneficial effects on preventing endothelial cell loss and improving endothelial function in patients with FECD undergoing phacoemulsification. Corneal densitometry showed reduced corneal light scattering in the ripasudil group after phacoemulsification, suggesting improved corneal endothelial function.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Cornea 医学-眼科学

CiteScore

5.20

自引率

10.70%

发文量

354

审稿时长

3-6 weeks

期刊介绍： For corneal specialists and for all general ophthalmologists with an interest in this exciting subspecialty, Cornea brings together the latest clinical and basic research on the cornea and the anterior segment of the eye. Each volume is peer-reviewed by Cornea''s board of world-renowned experts and fully indexed in archival format. Your subscription brings you the latest developments in your field and a growing library of valuable professional references. Sponsored by The Cornea Society which was founded as the Castroviejo Cornea Society in 1975.